Irvine Scientific, a world leader in the innovation and manufacture of Assisted Reproductive Technologies (ART), announced a new partnership agreement with Biotech, giving Irvine Scientific exclusive distribution rights for the CRYOLOCK vitrification device in selected countries worldwide.
Irvine Scientific is committed to providing a total system solutions approach by offering high quality vitrification media used for oocytes and embryos of all stages along with approved devices. CRYOLOCK has rapidly become one of the most highly respected vitrification devices in IVF laboratories.
This new partnership enables Irvine Scientific to expand its support of approved vitrification devices.
"We are confident that the addition of CRYOLOCK will allow us to support laboratories that prefer this proven and widely used device.
We are excited to provide an expanded set of vitrification devices to help customers achieve exceptional results." said Yuichi Nagano, President and CEO, Irvine Scientific.
"This partnership significantly strengthens the existing CRYOLOCK device and demonstrates Biotech Inc.’s commitment to expanding this exceptional product for use worldwide to the infertility market", said Jorge Parra, CRYOLOCK designer and CEO, Biotech.
Irvine Scientific, a member of JX Group, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians.
The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines.
Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support.